Centene Announces Changes to Its Board of Directors
Centene Corporation (NYSE: CNC) announced that Kenneth A. Burdick has retired from its board, effective July 28, 2026, and Paul J. Diaz has been appointed as a new director on the same date. Mr. Burdick had joined Centene's Board in January 2022 after previously serving as Executive Vice President of Products and Markets at Centene and CEO of WellCare Health Plans. Paul J. Diaz brings extensive healthcare leadership experience, having served as CEO of Myriad Genetics and Kindred Healthcare, among other roles. He is currently a Managing Partner at Cressey & Company and has prior board experience with DaVita and PharMerica. Both Mr. Burdick and Mr. Eppinger praised the contributions made by each to Centene's mission. Centene remains focused on its strategy of providing high-quality, cost-effective healthcare services to under-insured individuals across government-sponsored and commercial programs.
Topics: Corporate Governance Leadership